Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial
Andrew R. Branagan(Massachusetts General Hospital), Madhav V. Dhodapkar(Yale Cancer Center), Daniel Zelterman(Yale University), Chandra Sekhar Boddupalli, Dennis Cooper(Yale Cancer Center), Fangyong Li(Yale University), Geliang Gan(Yale University), Lin Zhang(Yale Cancer Center), Rakesh Verma(Harvard University), Thomas Ferencz(Yale Cancer Center), Stuart Seropian(Yale Cancer Center), Eamon Duffy(Auckland City Hospital), Terri L. Parker(Yale Cancer Center), Randy A. Albrecht(Icahn School of Medicine at Mount Sinai)
Cited by 48
Related Papers
Animal models for COVID-19
|Nature|2020|877
A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics
|Nature Biomedical Engineering|2021|433
Nephrin ectodomain engagement results in Src kinase activation, nephrin phosphorylation, Nck recruitment, and actin polymerization
|Journal of Clinical Investigation|2006|349